EVALUATION OF THE EFFECT OF FUROSEMIDE ON ULTRAFILTERABLE PLATINUM KINETICS IN PATIENTS TREATED WITH CIS-DIAMMINEDICHLOROPLATINUM

被引：16

作者：

DUMAS, M

DEGISLAIN, C

DATHIS, P

CHADOINTNOUDEAU, V

ESCOUSSE, A

GUERRIN, J

AUTISSIER, N

机构：

[1] CTR LUTTE CONTRE CANC GEORGES FRANCOIS LECLER,F-21000 DIJON,FRANCE

[2] FAC PHARM DIJON,CHIM ANALYT LAB,F-21000 DIJON,FRANCE

[3] HOP BOCAGE,DEPT INFORMAT MED,F-21000 DIJON,FRANCE

来源：

关键词：

D O I：

10.1007/BF00258455

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：37 / 40

页数：4

共 20 条

[1] BELT RJ, 1979, CANCER TREAT REP, V63, P1515
[2] CATTERSON R, 1983, RES COMMUN CHEM PATH, V41, P255
[3] THE MECHANISM OF RENAL CLEARANCE OF CISPLATIN (CIS-DICHLORODIAMMINE PLATINUM-II) AND ITS MODIFICATION BY FUROSEMIDE AND PROBENECID
DALEYYATES, PT
MCBRIEN, DCH
[J]. BIOCHEMICAL PHARMACOLOGY, 1982, 31 (13) : 2243 - 2246
[4] URINARY BETA-2-MICROGLOBULIN - EARLY INDICATOR OF HIGH-DOSE CISDIAMMINEDICHLOROPLATINUM NEPHROTOXICITY - INFLUENCE OF FUROSEMIDE
DEGISLAIN, C
DUMAS, M
DATHIS, P
LAUTISSIER, JL
ESCOUSSE, A
GUERRIN, J
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 18 (03) : 276 - 279
[5] DUMAS M, 1985, INT J CLIN PHARM TH, V23, P430
[6] CISPLATIN NEPHROTOXICITY - A SUMMARY OF PREVENTATIVE INTERVENTIONS
FINLEY, RS
FORTNER, CL
GROVE, WR
[J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (05): : 362 - 367
[7] FRICK GA, 1979, CANCER TREAT REP, V63, P13
[8] GUARINO AM, 1979, CANCER TREAT REP, V63, P1475
[9] PHARMACOKINETICS AND PROTEIN-BINDING OF CIS-DICHLORODIAMMINE PLATINUM (II) ADMINISTERED AS A ONE-HOUR OR AS A 20-HOUR INFUSION
GULLO, JJ
LITTERST, CL
MAGUIRE, PJ
SIKIC, BI
HOTH, DF
WOOLLEY, PV
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1980, 5 (01) : 21 - 26
[10] HAYES DM, 1977, CANCER, V39, P1372, DOI 10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO